

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

**RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JULY 10, 2019**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, on July 10, 2019, the Company held its Annual General Meeting (the “**AGM**”) at which all resolutions set out in the notice of the AGM dated June 10, 2019 (the “**Notice**”) were duly passed by way of poll.

Reference is made to the circular (the “**Circular**”) of the Company dated June 10, 2019. Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held at Units 2302–2305, 23/F, Tower One, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong on Wednesday, July 10, 2019 at 10:00 a.m., all the ordinary resolutions set out in the Notice (the “**Resolutions**”) were duly passed by way of poll at the AGM. The poll results in respect of the Resolutions were as follows:

ORDINARY RESOLUTIONS		Number of Shares Voted (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended March 31, 2019.	7,860,299,706 (99.94%)	4,734,197 (0.06%)
2.	(a) To re-elect:		
	(i) Mr. WANG Lei as a non-executive director of the Company;	7,852,415,802 (99.83%)	13,546,101 (0.17%)
	(ii) Mr. XU Hong as a non-executive director of the Company;	7,837,456,355 (99.64%)	28,505,548 (0.36%)
	(iii) Mr. LUO Tong as an independent non-executive director of the Company;	7,859,419,706 (99.92%)	6,542,197 (0.08%)
	(iv) Mr. WONG King On, Samuel as an independent non-executive director of the Company; and	7,850,367,060 (99.80%)	15,594,843 (0.20%)
	(v) Ms. HUANG Yi Fei, (Vanessa) as an independent non-executive director of the Company.	7,862,887,903 (99.96%)	3,074,000 (0.04%)
	(b) To authorize the board of directors of the Company to fix the directors’ remuneration.	7,862,775,963 (99.96%)	3,108,940 (0.04%)
3.	To re-appoint Ernst & Young as the auditor of the Company and to authorize the board of directors to fix their remuneration.	7,841,690,057 (99.69%)	24,271,846 (0.31%)
4.	To grant a general mandate to the directors of Company to issue and allot shares.	7,588,937,442 (96.48%)	277,024,461 (3.52%)
5.	To grant a general mandate to the directors of the Company to repurchase shares.	7,862,918,903 (99.96%)	3,028,000 (0.04%)
6.	To approve the addition of the aggregate amount of the shares repurchased as mentioned in resolution no. 5 to the aggregate amount that may be issued and allotted pursuant to resolution no. 4.	7,590,159,664 (96.49%)	275,792,239 (3.51%)

ORDINARY RESOLUTIONS		Number of Shares Voted (%)	
		For	Against
7.	To approve the grant of a mandate authorizing the directors of the Company to grant awards of options and/or restricted share units (the “RSUs”) pursuant to the share award scheme adopted by the Company on November 24, 2014 (the “Share Award Scheme”) in respect of a maximum number of the underlying new shares that is equivalent to 3 per cent. of the shares in issue as at the date of passing of this resolution during the period from the date of passing this resolution until the earlier of (a) conclusion of the Company’s next annual general meeting, (b) the end of the period within which the Company is required by any applicable law or its bye-laws to hold its next annual general meeting and (c) the date on which this resolution is varied or revoked by an ordinary resolution of the shareholders of the Company in general meeting (the “Applicable Period”) and to allot, issue and deal with shares underlying the options and/or RSUs granted pursuant to the Share Award Scheme during the Applicable Period as and when such options and/or RSUs vest.	7,708,175,599 (97.99%)	157,786,304 (2.01%)

Notes:

- (1) The full text of the resolutions is set out in the Notice.
- (2) As at the date of the AGM:
 - (a) the total number of Shares in issue was 11,712,533,464. Since the last monthly return submitted by the Company under Rule 13.25B of the Listing Rules on July 5, 2019, the Company had issued a total of 305,500 Shares due to the exercise of share options by certain employees of the Company under the Company’s share award scheme. Such share options were not exercised by a Director and hence a next day disclosure return was not submitted by the Company under Rule 13.25A(1) of the Listing Rules;

- (b) a total of 390 grantees under the Share Award Scheme held 172,369,753 Shares (which represented approximately 1.47% of the total issued Shares as at the date of the AGM) upon exercising and vesting of the Options and the RSUs (as applicable). Such grantees included, among others, (i) one Director, namely Mr. Wang Lei, having held 3,099,250 Shares as a result of the exercising and vesting of Options and RSUs granted to him, and (ii) other directors of the subsidiaries of the Company, having held 13,076,788 Shares in total as a result of the exercising and vesting of Options and RSUs (as applicable) granted to them. All such 390 grantees abstained from voting on Resolution no. 7 in relation to the 2019 Share Award Mandate. Except as disclosed herein and the extent that the Directors were aware of and having made all reasonable enquiries, none of the Directors and directors of the Company's subsidiaries, who were also Participants under the Share Award Scheme who had been granted any Share Awards, held any Share;
- (c) the total number of shares entitling the Shareholders to attend and vote for or against the Resolutions (other than Resolution no.7) at the AGM was 11,712,227,964 and the total number of share entitling the Shareholders to attend and vote for or against Resolution no.7 was 11,540,163,711; and
- (d) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the AGM was nil.
- (3) Tricor Secretaries Limited, the Company's branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.

As more than 50% of the total votes were cast in favour of each of Resolutions no. 1 to no. 7, all Resolutions were duly passed as ordinary resolutions of the Company.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
SHEN DIFAN
Chief Executive Officer and Executive Director

Hong Kong, July 10, 2019

As at the date of this announcement, the Board comprises eight Directors, of whom (i) two are executive Directors, namely Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei, (Vanessa).